抗 CD22/CD19 CAR-T 细胞疗法 CART2219.1 在成人和儿童复发/难治性 B-ALL 中的 I/II 期试验
A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.
在一项多中心I/II期试验中,所有患者(n=11;7名儿童,4名成人)在第28天均达到完全缓解(91%为微小残留病阴性)。
英文原题:Single-cell transcriptomics analysis reveals that the tumor-infiltrating B cells determine the indolent fate of papillary thyroid carcinoma.
本研究为早期PTC的细胞图谱提供了见解,揭示了惰性与进展性病例中不同的肿瘤和免疫微环境特征。这些发现促进了对惰性PTC生物学的理解,并支持可靠诊断和预后生物标志物的开发。
主动监测(AS)为惰性甲状腺乳头状癌(PTC)的管理提供了一种可行的替代手术干预的方案,有助于减少不必要的治疗。然而,AS的更广泛采用受到需要更可靠诊断标志物的制约。本研究旨在识别惰性与进展性PTC之间的差异,并为生物标志物开发和治疗策略寻找新靶点。
我们使用单细胞RNA测序(scRNA-seq)分析了10例早期PTC肿瘤的细胞差异。研究结果在另外25例肿瘤中通过细胞共培养、迁移实验、免疫荧光染色、流式细胞术以及癌症基因组图谱(TCGA)数据分析进行了验证。
肿瘤浸润性B细胞(TIL-B),尤其是生发中心B细胞(GC-B),在惰性PTC中更为丰富。这些细胞在惰性和进展性病例中均抑制甲状腺细胞增殖,尽管惰性PTC具有更高的招募外周B细胞的能力。在惰性病例中,TIL-B细胞表现出增殖增加,并在三级淋巴结构(TLS)内形成簇。PTPRC-CD22相互作用被确定为TIL-B细胞增殖的潜在驱动因素。与GC-B细胞相关的标志物,如LMO2,被强调为惰性PTC的潜在诊断和预后指标。
OBJECTIVE: Active surveillance (AS) offers a viable alternative to surgical intervention for the management of indolent papillary thyroid carcinoma (PTC), helping to minimize the incidence of unnecessary treatment. However, the broader adoption of AS is hindered by the need for more reliable diagnostic markers. This study aimed to identify the differences between indolent and progressive PTC and find new targets for biomarker development and therapeutic strategies. METHODS: We used single-cell RNA sequencing (scRNA-seq) to analyze cellular differences in 10 early-stage PTC tumors. Findings were validated in an additional 25 tumors using cell co-culture, migration assays, immunofluorescence staining, flow cytometry, and analysis of data from The Cancer Genome Atlas (TCGA). RESULTS: Tumor-infiltrating B cells (TIL-B), particularly germinal center B cells (GC-B), were more abundant in indolent PTC. These cells suppressed thyroid cell proliferation in both indolent and progressive cases, though indolent PTC had a higher capacity to recruit peripheral B cells. In indolent cases, TIL-B cells showed increased proliferation and formed clusters within tertiary lymphoid structures (TLS). PTPRC-CD22 interactions were identified as potential drivers of TIL-B cell proliferation. Markers linked to GC-B cells, such as LMO2, were highlighted as potential diagnostic and prognostic indicators for indolent PTC. CONCLUSION: This study provides insights into the cellular landscape of early-stage PTC, revealing distinct tumor and immune microenvironment features in indolent and progressive cases. These findings advance the understanding of indolent PTC biology and support the development of reliable diagnostic and prognostic biomarkers.
MEMBER ACCOUNT
登录成功会直接打开下一页。